Ditchcarbon
  • Contact
  1. Organizations
  2. Alexion Pharmaceuticals, Inc.
Public Profile
Research Pending

This profile hasn't yet passed our validation checks

Submit your email to push it up the queue

We'll prioritize this organization's research and notify you when detailed sustainability data becomes available.

Pharmaceutical Preparation Manufacturing
US
updated 12 days ago

Alexion Pharmaceuticals, Inc.

Company website

Alexion Pharmaceuticals, Inc., a leading biopharmaceutical company headquartered in the United States, is renowned for its innovative therapies in the field of rare diseases. Founded in 1992, Alexion has made significant strides in developing life-changing treatments, particularly in the areas of neurology, nephrology, and immunology. The company’s flagship products, including Soliris and Ultomiris, are unique in their ability to target complement-mediated diseases, setting new standards in patient care. With a strong market position, Alexion has achieved notable milestones, such as expanding its global reach across North America, Europe, and Asia. Committed to advancing science and improving patient outcomes, Alexion Pharmaceuticals continues to be a pivotal player in the biopharmaceutical industry.

DitchCarbon Score

How does Alexion Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

93

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Alexion Pharmaceuticals, Inc.'s score of 93 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.

96%

Let us know if this data was useful to you

Alexion Pharmaceuticals, Inc.'s reported carbon emissions

Inherited from AstraZeneca PLC

Alexion Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of AstraZeneca PLC, any climate commitments or emissions data may be inherited from its parent company. AstraZeneca has set ambitious climate targets, which include commitments to reduce greenhouse gas emissions across its operations. These targets are cascaded to Alexion Pharmaceuticals, reflecting a broader corporate strategy aimed at sustainability and climate resilience. While specific reduction targets for Alexion are not detailed, AstraZeneca's initiatives include participation in the Science Based Targets initiative (SBTi) and commitments to renewable energy through the RE100 initiative. These efforts underscore a commitment to reducing Scope 1, 2, and 3 emissions, although specific figures for Alexion are not disclosed. In summary, while Alexion Pharmaceuticals, Inc. does not currently report its own emissions data, it aligns with the climate commitments and reduction strategies of its parent company, AstraZeneca PLC, focusing on sustainability and emissions reduction across the pharmaceutical industry.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201520162017201920202021202220232024
Scope 1
298,498,000
000,000,000
000,000,000
-
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 2
322,319,000
000,000,000
000,000,000
-
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
-
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Alexion Pharmaceuticals, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Alexion Pharmaceuticals, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Alexion Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Genmab

DK
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Hikma Pharmaceuticals

GB
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Life Technologies Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 18 days ago

Exelixis, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 18 days ago

Celanese

US
•
Chemicals nec
Updated 11 days ago

Seagen Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 18 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251001.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy